Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions.
AbbVie Tracking for New Highs in 2024
Read Also
- M&As: Anticipated ‘deal value threshold’ norms Imminent, says CCI chief Ravneet Kaur
- A budget airline just made a big change passengers will like
- Govt. mulls new farm law to facilitate inter-State agriculture produce sale
- An unexpected airline just reported record profits
- The Side Hustle He Started at Age 15 Led to a $4 Billion Boon for Small Businesses: 'They Would Take a Chance on Me With Their Hard-Earned Money'
- SIDBI to finance purchase of Airbus copters in India
- How Motion Sensors Work
- The Best Leaders and Most Successful Entrepreneurs Don't Ignore These 6 Startup Strategies
- Hargreaves Lansdown launches cheaper alternative to existing managed fund range – is it any good?
- Red Lobster files for bankruptcy — what it means for your next seafood dinner
Latest MarketBeat
- MarketBeat Week in Review – 5/13 - 5/17
- Take-Two Interactive Software Offers 2nd Chance for Investors
- Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
- Analysts Still Want Double-Digit Upside Out of Applied Materials
- Baidu Stock Earnings Prove Ray Dalio Right about China?
- 3 Reasons Nvidia is on The Verge of a 4 Digit Stock Price
- Bargain Alert: Lululemon Shares Could Be About To Hit Rally Mode
- Bears Sent a False Alarm for Under Armour Stock
- Gamestop is Heading Back to $10 or Lower
- 3 Small Cap Techs Gaining Traction for Investors